Alopecia Areata
Alopecia areata (AA) is an autoimmune condition that causes sudden hair loss in patches, affecting both men and women. It can occur on the scalp or other areas of the body and may lead to complete hair loss in some cases.
Alopecia Areata: Baricitinib for Children
We are studying whether Baricitinib helps children aged 6 to under 18 with Alopecia Areata by comparing it to a placebo. This trial aims to find out if the medication can improve hair regrowth.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Do you have severe alopecia areata (AA) that has lasted for at least 1 year?
- Is your current episode of alopecia areata lasting at least 6 months and causing hair loss of 50% or more on your scalp?
- Have you had severe alopecia areata for less than 8 years?
- Are you currently experiencing any other types of hair loss or health problems that could affect the study?
- Have you used any topical treatments on your scalp in the last 4 weeks?
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Centre Hospitalier Regional Universitaire De Tours
Pedriatric Medicine
La Riche, France
Assistance Publique Hopitaux De Marseille
Dermatology
Marseille, France
Centre Hospitalier Universitaire De Nantes
Dermatology
Nantes, France
Sponsor: Eli Lilly & Co.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.